Nothing Special   »   [go: up one dir, main page]

WO2000058473A3 - Nucleic acids including open reading frames encoding polypeptides; 'orfx' - Google Patents

Nucleic acids including open reading frames encoding polypeptides; 'orfx' Download PDF

Info

Publication number
WO2000058473A3
WO2000058473A3 PCT/US2000/008621 US0008621W WO0058473A3 WO 2000058473 A3 WO2000058473 A3 WO 2000058473A3 US 0008621 W US0008621 W US 0008621W WO 0058473 A3 WO0058473 A3 WO 0058473A3
Authority
WO
WIPO (PCT)
Prior art keywords
orfx
open reading
reading frames
nucleic acids
frames encoding
Prior art date
Application number
PCT/US2000/008621
Other languages
French (fr)
Other versions
WO2000058473A2 (en
Inventor
Richard A Shimkets
Martin Leach
Original Assignee
Curagen Corp
Richard A Shimkets
Martin Leach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets, Martin Leach filed Critical Curagen Corp
Priority to JP2000608754A priority Critical patent/JP2004507202A/en
Priority to CA002383592A priority patent/CA2383592A1/en
Priority to EP00916677A priority patent/EP1165784A2/en
Priority to AU37745/00A priority patent/AU3774500A/en
Publication of WO2000058473A2 publication Critical patent/WO2000058473A2/en
Publication of WO2000058473A3 publication Critical patent/WO2000058473A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention provides open reading frames encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
PCT/US2000/008621 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; 'orfx' WO2000058473A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000608754A JP2004507202A (en) 1999-03-31 2000-03-31 Nucleic acid containing an open reading frame encoding a polypeptide; "ORFX"
CA002383592A CA2383592A1 (en) 1999-03-31 2000-03-31 2384891 acids including open reading frames encoding polypeptides; orfx
EP00916677A EP1165784A2 (en) 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; "orfx"
AU37745/00A AU3774500A (en) 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; "orfx"

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12760799P 1999-03-31 1999-03-31
US60/127,607 1999-03-31
US12763699P 1999-04-02 1999-04-02
US60/127,636 1999-04-02
US12772899P 1999-04-05 1999-04-05
US60/127,728 1999-04-05
US54076300A 2000-03-30 2000-03-30
US09/540,763 2000-03-30

Publications (2)

Publication Number Publication Date
WO2000058473A2 WO2000058473A2 (en) 2000-10-05
WO2000058473A3 true WO2000058473A3 (en) 2001-01-25

Family

ID=27494693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008621 WO2000058473A2 (en) 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Country Status (5)

Country Link
EP (1) EP1165784A2 (en)
JP (1) JP2004507202A (en)
AU (1) AU3774500A (en)
CA (1) CA2383592A1 (en)
WO (1) WO2000058473A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6482932B1 (en) * 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6528640B1 (en) * 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US7033772B1 (en) 1998-01-15 2006-04-25 Millennium Pharmaceuticals, Inc. Methods of identifying inhibitors of fatty acid transport proteins (FATP)
US6300096B1 (en) 1998-01-15 2001-10-09 Whitehead Institute For Biomedical Research Polynucleotides encoding fatty acid transport proteins
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US7241862B2 (en) 1998-05-15 2007-07-10 Genentech, Inc. Polypeptides that induce cell proliferation or induce fetal hemoglobin
WO2001062926A2 (en) * 2000-02-25 2001-08-30 Millennium Pharmaceuticals, Inc. 44576, a novel g-protein coupled receptor and uses therefor
WO2001066756A2 (en) * 2000-03-07 2001-09-13 Millenium Pharmaceuticals, Inc. 22105, a human thioredoxin family member and uses thereof
EP1593687A3 (en) * 1998-06-10 2006-10-18 Bayer Corporation Human genes differentially expressed in colon cancer
US20030003507A1 (en) 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7258973B2 (en) 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
US20030096391A1 (en) * 2000-12-22 2003-05-22 Millennium Pharmaceuticals, Inc. 17903, a novel human aminopeptidase and uses therefor
JP4315301B2 (en) * 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 Human H37 protein and cDNA encoding this protein
US7867731B2 (en) 1998-11-04 2011-01-11 Novartis Vaccines And Diagnostics, Inc. HX2004-6 polypeptide expressed in cancerous cells
US6743602B1 (en) 1999-07-26 2004-06-01 Chiron Corporation Polynucleotides differentially expressed in adenocarcinomas, polypeptides encoded thereby, and methods of use thereof
EP1141269A4 (en) * 1998-12-30 2003-03-26 Millennium Pharm Inc Secreted proteins and uses thereof
KR100468975B1 (en) * 1999-02-12 2005-02-02 제넨테크, 인크. Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same
ATE380195T1 (en) * 1999-03-08 2007-12-15 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING TUMORS
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
IL145514A0 (en) * 1999-03-19 2002-06-30 Aventis Pharm Prod Inc Akt nucleic acids, polypeptides, and uses thereof
NZ536320A (en) * 1999-03-23 2006-04-28 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU5173400A (en) * 1999-05-28 2000-12-18 Sugen, Inc. Protein kinases
WO2000075320A2 (en) * 1999-06-07 2000-12-14 Lexicon Genetics Incorporated Human genes and proteins encoded thereby
WO2000078953A2 (en) * 1999-06-17 2000-12-28 Incyte Genomics, Inc. Human transport proteins
DE19928021A1 (en) * 1999-06-18 2000-12-21 Basf Ag New nucleic acid encoding testis-specific calpain-11, useful for identifying specific inhibitors for treatment of fertility disorders
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
EP1228082A4 (en) * 1999-07-23 2005-11-16 Human Genome Sciences Inc 29 human secreted proteins
WO2001007614A1 (en) * 1999-07-26 2001-02-01 Chiron Corporation Polynucleotides differentially expressed in adenocarcinomas, polypeptides encoded thereby, and methods of use thereof
DE19936563A1 (en) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumor Associated Antigen
KR100543857B1 (en) * 1999-09-01 2006-01-23 제넨테크, 인크. Promotion or Inhibition of Angiogenesis and Cardiovascularization
US6818750B2 (en) * 1999-09-01 2004-11-16 The Burnham Institute Card proteins involved in cell death regulation
WO2001016313A1 (en) * 1999-09-02 2001-03-08 Smithkline Beecham P.L.C. Human gs protein regulator gene
WO2001016336A1 (en) * 1999-09-02 2001-03-08 Lexicon Genetics Incorporated Human calcium dependent proteases and polynucleotides encoding the same
US20020049312A1 (en) * 2000-05-23 2002-04-25 Turner C. Alexander Noel human thrombospondin-like proteins and polynucleotides encoding the same
US6329171B1 (en) * 1999-09-30 2001-12-11 Millennium Pharmaceuticals, Inc. 23484, A novel human ubiquitin protease
US7329529B2 (en) 1999-09-03 2008-02-12 Millennium Pharmaceuticals, Inc. Ubiqutin proteases
US20020045212A1 (en) * 2000-02-29 2002-04-18 Glucksmann Maria Alexandra Novel human GTPase activator proteins
AU6974900A (en) * 1999-09-07 2001-04-10 University Health Network A p53-induced protein with a death domain that can promote apoptosis
JP2003527092A (en) * 1999-09-15 2003-09-16 インサイト・ゲノミックス・インコーポレイテッド Proteins involved in cell differentiation
GB2370840A (en) * 1999-09-16 2002-07-10 Univ Mcgill Nrage nucleic acids and polypeptides and uses thereof
US6451994B1 (en) * 1999-09-27 2002-09-17 Millennium Pharmaceuticals, Inc. 23413, a novel human ubiquitin protease
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
GB9924060D0 (en) * 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
US20020081625A1 (en) * 1999-10-14 2002-06-27 John Ford Member of the immunoglobulin superfamily and uses thereof
US6420155B1 (en) * 1999-10-14 2002-07-16 Curagen Corporation Aortic carboxypeptidase-like protein and nucleic acids encoding same
EP1222264A1 (en) * 1999-10-19 2002-07-17 The Wellcome Trust Limited as Trustee to the Wellcome Trust Human sit4 associated proteins like (sapl) proteins and encoding genes; uses thereof
US20020081679A1 (en) * 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
EP1234042A1 (en) * 1999-10-25 2002-08-28 Millennium Pharmaceuticals, Inc. Protein 27875, a human adam-ts homolog
JP2003520030A (en) * 1999-11-05 2003-07-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 28 human secreted proteins
EP1230366A2 (en) 1999-11-10 2002-08-14 Lexicon Genetics Incorporated Human atpases and polynucleotides encoding the same
WO2001036602A2 (en) * 1999-11-15 2001-05-25 Pharmacia Italia S.P.A. Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
EP1244793A2 (en) * 1999-11-17 2002-10-02 Curagen Corporation Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
CA2491610A1 (en) * 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001040468A2 (en) * 1999-12-01 2001-06-07 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
AU2084601A (en) * 1999-12-10 2001-06-18 Biogen, Inc. Novel polypeptides and polynucleotides encoding same
US7115558B2 (en) * 1999-12-16 2006-10-03 Cytochroma Inc. P450RAI-2(P450 Cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof
AU1686701A (en) * 1999-12-21 2001-07-03 University Of Zurich Dispatched polypeptides
JP2003517838A (en) * 1999-12-23 2003-06-03 インサイト・ゲノミックス・インコーポレイテッド Human kinase
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ATE466882T1 (en) * 2000-01-12 2010-05-15 Univ Yale NOGO RECEPTOR-MEDIATED BLOCKADE OF AXONAL GROWTH
WO2001057203A1 (en) * 2000-02-01 2001-08-09 Taisho Pharmaceutical Co.,Ltd. NOVEL GENE tig104α AND PROTEIN TIG104α ENCODED THEREBY
AU2001233156A1 (en) * 2000-02-01 2001-08-14 Human Genome Sciences, Inc. Bcl-2-like polynucleotides, polypeptides, and antibodies
US7335749B2 (en) 2000-02-09 2008-02-26 The United States Of America As Represented By The Department Of Health And Human Services Tumor suppressor gene, p47Ing3
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
SE0100472L (en) * 2000-02-18 2001-08-19 Hoffmann La Roche New metalloproteases having thrombospondome domains and nucleic acid compositions encoding these
DE10007468A1 (en) * 2000-02-18 2001-08-23 Basf Lynx Bioscience Ag New central nervous protein that modulates K · + · currents
GB0004196D0 (en) * 2000-02-19 2000-04-12 Smithkline Beecham Plc Novel compounds
US20040033509A1 (en) 2000-07-18 2004-02-19 Millennium Pharmaceuticals, Inc. Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
US6864078B2 (en) 2000-02-29 2005-03-08 Millennium Pharmaceuticals, Inc. 14790, novel protein kinase molecule and uses therefor
WO2001064906A1 (en) * 2000-02-29 2001-09-07 Millennium Pharmaceuticals, Inc. Transferase 32253 and use therefor
WO2001064905A2 (en) * 2000-02-29 2001-09-07 Millennium Pharmaceuticals, Inc. 2504, 15977, and 14760, novel protein kinase family members and uses therefor
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001245354A1 (en) * 2000-03-02 2001-09-12 Human Genome Sciences, Inc. Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
US20040023227A1 (en) * 2000-03-02 2004-02-05 Keizo Inoue Dna encoding squalene epoxidase promoter
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
WO2001090322A2 (en) * 2000-05-19 2001-11-29 Millennium Pharmaceuticals, Inc. 32244, a novel human amp-binding enzyme and uses thereof
US20020055159A1 (en) * 2000-06-15 2002-05-09 Meyers Rachel A. 23680,a novel human aminotransferase and uses therefor
JP2003526369A (en) * 2000-03-10 2003-09-09 キュラジェン コーポレイション Novel polynucleotides and nucleic acids encoding the same
DE60124380T2 (en) * 2000-03-22 2007-10-11 Curagen Corp., New Haven ANGIOGENESIS ASSOCIATED PROTEINS AND NUCLEIC ACID CODING THEREFOR
WO2001073043A2 (en) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 32451, a human ubiquitin conjugating enzyme-like molecule and uses thereof
JP2001335598A (en) * 2000-03-24 2001-12-04 Takeda Chem Ind Ltd New protein, method for producing the same and use thereof
AU2001252957A1 (en) * 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. Human methyl transferase family member, 25552, and uses thereof
AU2001249421B2 (en) * 2000-03-24 2006-09-07 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
EP1266007A1 (en) * 2000-03-24 2002-12-18 MERCK PATENT GmbH Human survivin interacting protein 1 (sip-1)
FR2806739B1 (en) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph GENES INVOLVED IN INFLAMMATORY BOWEL DISEASES AND THEIR USE
EP1138765A1 (en) * 2000-03-27 2001-10-04 Leadd B.V. Apoptin-associating proteins AAP-5 and AAP-6
EP1138768A3 (en) * 2000-03-27 2002-08-07 Leadd B.V. Apoptin-associating protein AAP-5
AU2001244615A1 (en) * 2000-03-29 2001-10-08 Kyowa Hakko Kogyo Co. Ltd. Proliferative glomerular nephritis-associated gene
US20030198953A1 (en) * 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
ES2328448T7 (en) * 2000-03-31 2012-03-16 Millennium Pharmaceuticals Inc. 16836, A MEMBER OF THE HUMAN PHOSPHOLIPASE C FAMILY AND ITS USES.
JP2003530111A (en) 2000-04-07 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Human pyruvate dehydrogenase phosphatase
US7033810B2 (en) 2000-04-18 2006-04-25 Amgen Inc. Sitosterolemia susceptibility gene (SSG): compositions and methods of use
US20030119081A1 (en) * 2001-10-29 2003-06-26 Millennium Pharmaceuticals, Inc. 32235, a human aminotransferase family member and uses therefor
JP2003530877A (en) * 2000-04-26 2003-10-21 ピーイー コーポレーション （エヌワイ） Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US20020019348A1 (en) * 2000-08-02 2002-02-14 Applera Corporation Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
CA2407435A1 (en) * 2000-04-28 2001-11-08 Incyte Genomics, Inc. Rna metabolism proteins
US6808876B1 (en) 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
CA2407887A1 (en) * 2000-05-02 2001-11-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natrium-calcium exchanger protein
US7034135B2 (en) 2000-05-03 2006-04-25 Millennium Pharmaceuticals, Inc. Molecules of the NBS/LRR protein family and uses thereof
AU2001259420A1 (en) * 2000-05-03 2001-11-12 Millennium Pharmaceuticals, Inc. Novel molecules of the nbs/lrr protein family and uses thereof
US20020132298A1 (en) * 2000-11-14 2002-09-19 Millennium Pharmaceuticals, Inc. 67118, 67067, and 62092, human proteins and methods of use thereof
EP1278863A2 (en) * 2000-05-12 2003-01-29 MERCK PATENT GmbH Human serine-threonine kinase-4
WO2001088135A2 (en) * 2000-05-15 2001-11-22 Curagen Corporation G-protein coupled receptor proteins and nucleic acids encoding same
EP1158049A1 (en) * 2000-05-26 2001-11-28 Aeomica, INC. Myosin-like gene expressed in human heart and muscle
WO2001092524A2 (en) * 2000-05-26 2001-12-06 Aeomica, Inc. Myosin-like gene expressed in human heart and muscle
GB2380197A (en) * 2000-05-26 2003-04-02 Aeomica Inc Myosin-like gene expressed in human heart and muscle
EP1666594A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
CA2412876A1 (en) * 2000-06-14 2002-12-13 Sankyo Company Limited Ceramide kinase and dna encoding the same
WO2001096561A1 (en) * 2000-06-16 2001-12-20 Merck Patent Gmbh Hunc-2, human member of unc-protein family
EP1176200A3 (en) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances
EP1295940A4 (en) 2000-06-26 2005-01-12 Ajinomoto Kk Polypeptides, use thereof and process for producing the same
EP1309684A2 (en) * 2000-06-27 2003-05-14 Curagen Corporation Polynucleotides and polypeptides encoded thereby
EP1320590A2 (en) * 2000-07-13 2003-06-25 Millennium Pharmaceuticals, Inc. 47885, a novel human ubiquitin-activating enzyme and uses therefor
WO2002006318A2 (en) * 2000-07-18 2002-01-24 Board Of Regents, The University Of Texas System Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
EP1174502A1 (en) * 2000-07-18 2002-01-23 Schering Corporation Type 2 dendritic cell precursor derived coding nucleic acids and related compositions and methods
EP1307557A2 (en) * 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
ATE329025T1 (en) * 2000-08-18 2006-06-15 Merck Patent Gmbh MFQ-111, A HUMAN GTPASE-LIKE PROTEIN
AU2001285224A1 (en) * 2000-08-24 2002-03-04 Incyte Genomics, Inc. Kidney-specific protein
AU2001293778A1 (en) * 2000-08-28 2002-03-13 Lion Bioscience Ag Novel cofactors of the pregnane x receptor and methods of use
AU2001288600A1 (en) 2000-08-31 2002-03-13 Millennium Pharmaceuticals, Inc. 62112, a novel human dehydrogenase and uses thereof
CA2460014A1 (en) * 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
CA2423108A1 (en) 2000-09-22 2003-03-19 Kyowa Hakko Kogyo Co., Ltd. .beta.-catenin nuclear localizing protein
WO2002024744A2 (en) * 2000-09-25 2002-03-28 Millennium Pharmaceuticals, Inc. 49938, a human phospholipid transporter and uses therefor
AU2001294684A1 (en) * 2000-09-29 2002-04-08 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
US20040138414A1 (en) * 2000-09-29 2004-07-15 Henry Yue Secreted proteins
US20020150916A1 (en) * 2000-10-05 2002-10-17 Rachel Meyers 43716, a novel human G-protein and uses thereof
US20030124704A1 (en) 2000-10-06 2003-07-03 Strittmatter Stephen M. Nogo receptor homologs
MXPA03003191A (en) * 2000-10-12 2004-12-03 Ferring Bv Novel serine protease genes related to dppiv.
AU2002221676A1 (en) * 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human acyl-coa dehydrogenase
US20020119518A1 (en) * 2000-10-17 2002-08-29 Merkulov Gennady V. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2001295778A1 (en) * 2000-10-20 2002-04-29 Inpharmatica Limited Novel cysteine proteases and uses thereof
FR2822165B1 (en) * 2000-10-24 2004-12-24 Aventis Pharma Sa NUCLEIC ACID REGULATING THE ABCA7 GENE, MOLECULES MODULATING ITS ACTIVITY AND THERAPEUTIC APPLICATIONS
EP1334186A2 (en) * 2000-10-24 2003-08-13 Aventis Pharma S.A. Nucleic acid generating the abca7 gene, molecules modulating its activity and therapeutic applications
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
WO2002036741A2 (en) * 2000-10-30 2002-05-10 Bristol-Myers Squibb Company Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
WO2002036781A2 (en) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Regulation of human glutathione-s-transferase
US20030032776A1 (en) * 2000-11-02 2003-02-13 Feder John N. Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1
EP1337559A2 (en) * 2000-11-17 2003-08-27 Bayer Ag Regulation of human nmda receptor
AU2002228612A1 (en) 2000-11-22 2002-06-03 Bristol-Myers Squibb Company Cloning and expression of human slap-2: a novel sh2/sh3 domain-containing human slap homologue having immune cell-specific expression
CA2324663A1 (en) * 2000-11-27 2002-05-27 The Hospital For Sick Children A novel adapter gene
WO2002044358A2 (en) * 2000-11-28 2002-06-06 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3
WO2002046402A2 (en) * 2000-12-05 2002-06-13 Bayer Aktiengesellschaft Regulation of human patched-like protein
WO2002081667A2 (en) * 2000-12-05 2002-10-17 Incyte Genomics, Inc. Ligases
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US20040082051A1 (en) * 2000-12-14 2004-04-29 Zhimin Zhu Regulation of human uridine kinase
JP3749709B2 (en) * 2001-01-09 2006-03-01 株式会社Ｇｂｓ研究所 Human glioma antigen and preparation method thereof
US7122345B2 (en) 2001-01-09 2006-10-17 Curagen Corporation Nucleic acid encoding a NOVX13 polypeptide
WO2002055707A2 (en) * 2001-01-10 2002-07-18 Rigel Pharmaceuticals Inc Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen
US6605710B2 (en) * 2001-01-11 2003-08-12 Board Of Trustees Of Michigan State University Gene whose expression promotes differentiation of myeloid progenitor cells into neutrophils and/or monocytes/macrophages
US20020119523A1 (en) * 2001-01-17 2002-08-29 Millennium Pharmaceuticals, Inc. 67073, a human phospholipid transporter family member and uses therefor
JPWO2002057444A1 (en) * 2001-01-22 2004-05-20 近藤　科江 Human apoptosis-related gene and its product, human apoptosis-related protein
JP2005504503A (en) * 2001-02-06 2005-02-17 インサイト・ゲノミックス・インコーポレイテッド Receptors and membrane-related proteins
US20040132035A1 (en) * 2001-02-07 2004-07-08 Daemen Matthias Joseph A P Markers of unstable atherosclerotic plaques
WO2002064783A2 (en) * 2001-02-09 2002-08-22 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
AU2002250911A1 (en) * 2001-02-12 2002-08-28 Bayer Aktiengesellschaft Isolated polynucleotides encoding putative tyrosine kinase
AU2002247716A1 (en) * 2001-02-14 2002-08-28 Axaron Bioscience Ag Proteins 7b6 and 11b4 and dna sequences encoding the same
GB0104440D0 (en) * 2001-02-22 2001-04-11 Oxford Biomedica Ltd Novel genes
CA2441006A1 (en) * 2001-03-08 2002-09-19 Hyseq, Inc. Methods and materials relating to fibulin-like polypeptides and polynucleotides
EP1373526A4 (en) * 2001-03-08 2006-01-25 Curagen Corp Therapeutic polypeptides, nucleic acids encoding same, and methodes of use
WO2002074906A2 (en) * 2001-03-16 2002-09-26 Eli Lilly And Company Lp mammalian proteins; related reagents
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
US20020168668A1 (en) * 2001-03-27 2002-11-14 Millennium Pharmaceuticals, Inc. 14691, a human glutamate receptor family member and uses therefor
CA2442743A1 (en) * 2001-03-27 2002-12-12 Human Genome Sciences, Inc. Human secreted proteins
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
EP1390057A4 (en) * 2001-04-03 2005-10-12 Curagen Corp Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use
ATE512216T1 (en) 2001-04-10 2011-06-15 Agensys Inc NUCLEIC ACID AND THIS CORRESPONDING PROTEIN, CALLED 184P1E2, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6607895B2 (en) 2001-04-16 2003-08-19 Lexicon Genetics Incorporated Human adenylsuccinate synthetase and polynucleotides encoding the same
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
CA2443617C (en) * 2001-04-17 2013-12-10 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
EP1383533A4 (en) * 2001-04-23 2006-11-02 Curagen Corp Proteins and nucleic acids encoding same
WO2002087507A2 (en) * 2001-04-27 2002-11-07 Sunnybrook & Women's College Health Sciences Centre Breast cancer-associated genes and uses thereof
AUPR470101A0 (en) 2001-05-02 2001-05-24 Murdoch Childrens Research Institute, The A molecular marker
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
WO2002097088A1 (en) 2001-05-29 2002-12-05 Human Cell Systems, Inc. Testicular carnitine transporter and its gene
AU2002327176A1 (en) * 2001-06-06 2002-12-16 Human Genome Sciences, Inc. 20 human secreted proteins
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EG26529A (en) * 2001-06-11 2014-01-27 مونسانتو تكنولوجى ل ل سى Cotton event mon 15985 and compositions and methods for detection thereof
US7488587B2 (en) * 2001-06-19 2009-02-10 The J. David Gladstone Institutes Histone deacetylase and methods of use thereof
WO2003000727A2 (en) * 2001-06-21 2003-01-03 Isis Innovation Limited Atopy
AT410945B (en) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Diagnosis of multiple sclerosis or tumors, by detecting absence of wild-type stem cell factor-apoptosis response gene, or the derived protein, also new nucleic acids
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
PL367675A1 (en) * 2001-07-05 2005-03-07 Wyeth Aggrecanase molecules
JP4702819B2 (en) * 2001-08-01 2011-06-15 生化学工業株式会社 Chondroitin synthase
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
AU2002367997A1 (en) * 2001-08-15 2003-12-19 Centre National De La Recherche Scientifique (Cnrs) Sut-2 and sut-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
WO2003027279A1 (en) * 2001-09-25 2003-04-03 Sony Corporation p300 HISTONE ACETYLASE INHIBITOR
DE10148037A1 (en) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Use of the protease activating the blood coagulation factor VII for the prophylaxis and therapy of vaso-proliferative diseases
WO2003031627A1 (en) * 2001-09-28 2003-04-17 Hokkaido Technology Licensing Office Co., Ltd. Platelet-origin polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2003063769A2 (en) * 2001-10-26 2003-08-07 Incyte Genomics, Inc. Vesicle-associated proteins
WO2003037930A1 (en) * 2001-10-29 2003-05-08 Kazusa Dna Research Institute Foundation Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same
GB2381526A (en) * 2001-11-03 2003-05-07 Sequenom Inc Detection of predisposition to osteoporosis
ATE553120T1 (en) 2001-11-16 2012-04-15 Eisai R&D Man Co Ltd PROTEINS OF THE JEAP FAMILY, COMPONENTS OF THE TIGHT CONNECTIONS OF THE EXOCRINE GLANDS
EP1451214A2 (en) 2001-11-26 2004-09-01 Hybrigenics Protein-protein interactions in human immunodeficiency virus
AUPR913901A0 (en) * 2001-11-27 2001-12-20 Children's Medical Research Institute Muscle transcription factors
WO2003048317A2 (en) * 2001-11-30 2003-06-12 Children's Hospital Medical Center Antibodies to magmas and uses thereof
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
JP2005527191A (en) 2001-12-18 2005-09-15 アンドキューブ ソシエタ パー アクシオン シンプリフィー Novel cell death-related proteins and THAP1 and PAR4 pathways in controlling apoptosis
WO2003064654A1 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Human serine/threonine protein kinase
JP2003252801A (en) * 2002-02-27 2003-09-10 Japan Science & Technology Corp Method for using pituitary-specific gene
AU2003218208A1 (en) 2002-03-19 2003-10-08 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
AU2003220274A1 (en) 2002-03-22 2003-10-13 Munin Corporation Cloning and characterization of g+c-rich promoter binding protein
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
AU2003240572A1 (en) * 2002-05-30 2003-12-19 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003260618A1 (en) * 2002-06-24 2004-01-06 Exonhit Therapeutics Sa Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
GB0215406D0 (en) * 2002-07-03 2002-08-14 Inpharmatica Ltd Protein
US7122358B2 (en) 2002-07-09 2006-10-17 Bristol-Myers Squibb Company Testis-specific tubulin tyrosine-ligase-like protein, BGS42
WO2004005487A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
US20080145928A1 (en) 2002-07-25 2008-06-19 Shuki Mizutani Factor Taking Part in Transcription Control
WO2004012817A2 (en) * 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
DE10309368A1 (en) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmaceutical preparation with RNA as a cofactor of hemostasis
US7408048B2 (en) 2002-08-09 2008-08-05 Melbourne Health Mammalian grainyhead transcription factors
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2497337A1 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of psoriasis
WO2004031731A2 (en) * 2002-10-02 2004-04-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for controlling proliferation of cells
AU2003291990A1 (en) * 2002-10-25 2004-05-13 Technische Universitaet Muenchen Nipa, a nuclear interacting partner of anaplastic lymphoma kinase, polypeptides and use thereof
MXPA05005237A (en) * 2002-11-15 2005-08-16 Univ Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions.
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
AU2003297696A1 (en) * 2002-12-05 2004-06-30 Diadexus, Inc. Compositions,splice variants and methods relating to breast specific genes and proteins
EP1576005A2 (en) * 2002-12-27 2005-09-21 Applied Research Systems ARS Holding N.V. Notch-like polypeptides
WO2004070025A2 (en) * 2003-02-05 2004-08-19 Juan Saus Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
PL2248899T3 (en) 2003-03-19 2015-10-30 Biogen Ma Inc NOGO receptor binding protein
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
CA2537844A1 (en) * 2003-09-05 2005-03-17 Cellzome Ag Treatment of neurodegenerative diseases
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
MXPA06011851A (en) 2004-04-14 2006-12-14 Genentech Inc Compositions and methods for modulating vascular development.
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
US20090239793A1 (en) * 2004-09-24 2009-09-24 Isabella Caniggia Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
WO2006094813A2 (en) * 2005-03-10 2006-09-14 Nascacell Technologies Ag. Dimeric or multimeric microproteins
EP1904091A4 (en) 2005-07-07 2009-12-23 Univ Yale Compositions and methods for suppressing axonal growth inhibition
PL1904104T3 (en) 2005-07-08 2014-02-28 Biogen Ma Inc Sp35 antibodies and uses thereof
US7811787B2 (en) 2006-04-25 2010-10-12 Bristol-Myers Squibb Company Polynucleotides encoding human SLAP-2 variant, hSLAP-2v3
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
DE102008045696A1 (en) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulocyte HNA-3a / b antigen
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2010111198A1 (en) 2009-03-23 2010-09-30 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
CN102459338A (en) 2009-05-08 2012-05-16 霍夫曼-拉罗奇有限公司 Humanized anti-EGFL 7 antibodies and methods of use thereof
MX2014013950A (en) 2012-05-14 2015-02-17 Biogen Idec Inc Lingo-2 antagonists for treatment of conditions involving motor neurons.
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015082525A1 (en) * 2013-12-03 2015-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Mafb mutants and uses thereof
MX2017009038A (en) 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.
CN112190710B (en) * 2020-10-28 2021-07-30 江苏省人民医院（南京医科大学第一附属医院） Application of lipid-derived polypeptide in preparation of metastatic breast cancer targeted drug
WO2022212928A1 (en) * 2021-04-02 2022-10-06 The Regents Of The University Of California Modified viruses and viral particles, methods of making, and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLE S.T.: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.", NATURE, vol. 393, 11 June 1998 (1998-06-11), XP002144873 *
LAMERDIN J.E.: "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster.", EMEST DATABASE ENTRY, 8 February 1999 (1999-02-08), XP002144874 *
M.D. ADAMS ET AL.: "The genome sequence of Drosophila melanogaster.", SCIENCE, vol. 287, 24 March 2000 (2000-03-24), pages 2185 - 2195, XP002144875 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Also Published As

Publication number Publication date
EP1165784A2 (en) 2002-01-02
JP2004507202A (en) 2004-03-11
CA2383592A1 (en) 2000-10-05
AU3774500A (en) 2000-10-16
WO2000058473A2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
WO2001049729A8 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2000078802A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001036638A8 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001085767A3 (en) Human proteins polynucleotides encoding them and methods of using the same
WO2001068851A3 (en) Polypeptides and nucleic acids encoding same
WO2001036635A3 (en) Neurite outgrowth-promoting factor homologue and nucleic acids encoding same
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2001023572A3 (en) Polynucleotides and polypeptides encoded thereby
WO2001032874A3 (en) Polypeptides and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383592

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 608754

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916677

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 37745/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000916677

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916677

Country of ref document: EP